Eiko LifesciencesBOM:540204 -1.43%78 Net Margin % is 7.09% as of Mar. 2026, which is 38% above its 10-year median of 5.12. GuruFocus rates BOM:540204 with a GF Score™ of 78/100 and a GF Value™ of ₹78.58 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,580 Chemicals companies, Eiko Lifesciences ranks better than 70.95% on this metric.
The historical rank and industry rank for Eiko Lifesciences's Net Margin % or its related term are showing as below:
BOM:540204'
s Net Margin % Range Over the Past 10 Years
Min: -10.47 Med: 5.12 Max: 42.98
Current: 8.53
BOM:540204's Net Margin % is ranked better than 70.95% of 1580
companies
in the Chemicals industry
Industry Median: 3.905
vs BOM:540204: 8.53
Eiko Lifesciences (BOM:540204) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Eiko Lifesciences Net Margin % Related Terms
Eiko Lifesciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Eiko Lifesciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540204 vs LIN, SHW, ECL: Net Margin % Comparison
For the Specialty Chemicals subindustry, Eiko Lifesciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiko Lifesciences Net Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Eiko Lifesciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Eiko Lifesciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eiko Lifesciences (BOM:540204) has a Net Margin % of 7.09% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Eiko Lifesciences and its competitors. This is 38% above median its historical median of 5.12. According to the industry distribution chart, Eiko Lifesciences ranks #459 out of 1580 companies in the Chemicals industry, placing it in the top 29.1%.
Is Eiko Lifesciences' Net Margin % too high?
Eiko Lifesciences' current Net Margin % of 7.09% is 38% above median its 10-year median of 5.12. The Chemicals industry median Net Margin % is 3.91. Eiko Lifesciences' value of 7.09% is 81.6% above this industry median. Based on the distribution chart, Eiko Lifesciences ranks #459 out of 1580 companies in the Chemicals industry, which is above the industry midpoint. Overall, Eiko Lifesciences has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eiko Lifesciences' Net Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Eiko Lifesciences ranks #459 out of 1580 companies for Net Margin %. This puts Eiko Lifesciences in the upper half of its industry. The industry median Net Margin % is 3.91. Eiko Lifesciences' value of 7.09% is 81.6% above this benchmark. While the company's 10-year median is 5.12 vs. the industry median of 3.91, Eiko Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Chemicals company?
The median Net Margin % among Chemicals companies is 3.91, based on 1,580 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiko Lifesciences's current Net Margin % of 7.09% is 81.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Eiko Lifesciences and its competitors. For the Chemicals industry, the median Net Margin % is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiko Lifesciences's current Net Margin % is 7.09%, which is 38% above median its own 10-year median of 5.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiko Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eiko Lifesciences (BOM:540204) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹78.58, compared to a current price of ₹49.72 — trading 36.7% below its estimated fair value. The current Net Margin % is 7.09%, which is 38% above median its 10-year median of 5.12 and 81.6% above the Chemicals industry median of 3.91. Eiko Lifesciences' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Eiko Lifesciences (BOM:540204), the current Net Margin % is 7.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eiko Lifesciences (BOM:540204) Overvalued in 2026?
Based on GuruFocus' analysis, Eiko Lifesciences stock appears to be undervalued.
The current stock price of ₹49.72 is trading 36.7% below its estimated GF Value™ of ₹78.58.
GuruFocus considers Eiko Lifesciences to be Significantly Undervalued.
Key valuation signals for BOM:540204:
Net Margin %: 7.09% (38% above median its 10-year median of 5.12)
GF Value™: ₹78.58 vs. price of ₹49.72 (36.7% below fair value)
Industry Position: 81.6% above the Chemicals median (#459 of 1580)
No single metric tells the full story. See the BOM:540204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eiko Lifesciences Ltd is a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and pharma intermediates.. The company's segment includes Agrochemicals, Oleo Chemicals, Pharmaceuticals, Food Additives, clinical research, development, and Logistics. Geographically, the company generates the majority of its revenue from the Domestic market.
78GF Score
Get the complete analysis for BOM:540204
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540204 has been successfully added to your 
